NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Osteosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Osteosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Osteosarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Osteosarcoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Osteosarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Osteosarcoma Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Osteosarcoma Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Osteosarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Osteosarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Osteosarcoma Therapeutics market landscape? Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Osteosarcoma Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Symptoms 9
2.5 Staging of Osteosarcoma 9
2.5.1 American Joint Committee on Cancer (AJCC) Staging System 9
2.6 Diagnosis of Osteosarcoma 12
2.6.1 Imaging Techniques 12
2.6.2 Biopsy 15
2.6.3 Blood Tests 15
2.7 Treatment Options by Stage 15
2.7.1 Localized Osteosarcoma 15
2.7.2 Metastatic Osteosarcoma 15
2.7.3 Recurrent Osteosarcoma 15
2.8 Treatment and Management pattern of Osteosarcoma 15
2.8.1 Surgery 15
2.8.2 Radiation Therapy 16
2.8.3 Chemotherapy 16
2.9 GlobalData Pipeline Report Guidance 17
3 Osteosarcoma Therapeutics: Market Characterization 18
3.1 Osteosarcoma Therapeutics Market Size, Global, 2005-2010 18
3.2 Osteosarcoma Therapeutics Market Forecast, Global, 2010-2017 19
3.3 Osteosarcoma Therapeutics Market Size, The US, 2005-2010 20
3.4 Osteosarcoma Therapeutics Market Forecast, The US, 2010-2017 21
3.5 Osteosarcoma Therapeutics Market Size, France, 2005-2010 22
3.6 Osteosarcoma Therapeutics Market Forecast, France, 2010-2017 23
3.7 Osteosarcoma Therapeutics Market Size, Germany 2005-2010 24
3.8 Osteosarcoma Therapeutics Market Forecast, Germany, 2010-2017 25
3.9 Osteosarcoma Therapeutics Market Size, Italy, 2005-2010 26
3.10 Osteosarcoma Therapeutics Market Forecast, Italy, 2010-2017 27
3.11 Osteosarcoma Therapeutics Market Size, Spain, 2005-2010 28
3.12 Osteosarcoma Therapeutics Market Forecast, Spain, 2010-2017 29
3.13 Osteosarcoma Therapeutics Market Size, The UK, 2005-2010 30
3.14 Osteosarcoma Therapeutics Market Forecast, The UK, 2010-2017 31
3.15 Osteosarcoma Therapeutics Market Size, Japan, 2005-2010 32
3.16 Osteosarcoma Therapeutics Market Forecast, Japan, 2010-2017 33
3.17 Drivers and Barriers for the Osteosarcoma Therapeutics Market 34
3.17.1 Drivers for the Osteosarcoma Therapeutics Market 34
3.17.2 Barriers for the Osteosarcoma Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 35
4 Osteosarcoma Therapeutics: Competitive Assessment 36
4.1 Overview 36
4.1.1 Strategic Competitor Assessment 36
4.2 Major Marketed Product Profiles in the Osteosarcoma Therapeutics Market 37
4.2.1 Drugs Influencing Structure and Function of Deoxyribonucleic Acid (DNA) 37
4.2.2 Drugs Inhibiting Biosynthesis of Nucleic Acids 38
4.2.3 Drugs Interfering with Microtubule Assembly 39
4.3 Key Takeaway 39
5 Osteosarcoma Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Osteosarcoma Therapeutics Pipeline, Pipeline by Phases of Development 41
5.3.1 Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41
5.3.2 Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41
5.3.3 Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42
5.3.4 Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42
5.4 Osteosarcoma Therapeutics, Pipeline by Mechanism of Action 43
5.5 Technology Trends Analytic Framework 44
5.6 Osteosarcoma Therapeutics Pipeline by Monotherapy and Combination Therapy 46
5.7 Osteosarcoma Therapeutics, Promising Drugs Under Clinical Development 47
5.8 Molecule Profile for Promising Drugs Under Clinical Development 48
5.8.1 Ridaforolimus (MK8669, AP23573, Deforolimus) 48
5.8.2 Mepact (mifamurtide) 49
5.8.3 Rexin-G 49
5.9 Key Takeaway 50
6 Osteosarcoma Therapeutics: Clinical Trials Mapping 51
6.1 Clinical Trials by Country (US, EU5 and Japan) 51
6.2 Clinical Trials by Phase 52
6.3 Clinical Trials by Trial Status 53
6.4 Prominent Sponsors 54
6.5 Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials 56
7 Osteosarcoma Therapeutics: Strategic Assessment 57
7.1 Key Events Impacting the Future Market 57
7.2 Osteosarcoma Therapeutics: Implications for Future Market Competition 58
8 Osteosarcoma Therapeutics: Future Players 59
8.1 Introduction 59
8.2 Company Profiles 60
8.2.1 Millennium Pharmaceuticals, Inc. 60
8.2.2 Merck & Co 62
8.2.3 ZIOPHARM Oncology, Inc 68
8.2.4 Oncolytics Biotech Inc. 70
8.2.5 Epeius Biotechnologies Corporation 72
8.2.6 Hawthorn Pharmaceuticals, Inc. 73
8.2.7 Other Companies in the Osteosarcoma Therapeutics Market 74
9 Osteosarcoma Therapeutics: Licensing and Partnership Deals 75
10 Osteosarcoma Therapeutics: Appendix 76
10.1 Market Definitions 76
10.2 Abbreviations 76
10.3 Methodology 77
10.3.1 Coverage 77
10.3.2 Secondary Research 77
10.3.3 Forecasting 78
10.3.4 Primary Research 81
10.3.5 Expert Panel Validation 81
10.4 Contact Us 81
10.5 Disclaimer 81
10.6 Bibliography 82
1.1 List of Tables
Table 1: Histological Classification of Osteosarcoma - WHO 8
Table 2: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 20052010 18
Table 3: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 20102017 19
Table 4: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 20052010 20
Table 5: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 20102017 21
Table 6: Osteosarcoma Therapeutics Market, France, Revenue ($m), 20052010 22
Table 7: Osteosarcoma Therapeutics Market, France, Forecast ($m), 20102017 23
Table 8: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 20052010 24
Table 9: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 20102017 25
Table 10: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 20052010 26
Table 11: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 20102017 27
Table 12: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 20052010 28
Table 13: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 20102017 29
Table 14: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 20052010 30
Table 15: Osteosarcoma Therapeutics Market, The UK, Forecasts ($m), 20102017 31
Table 16: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 20052010 32
Table 17: Osteosarcoma Therapeutics Market, Japan, Forecasts ($m), 20102017 33
Table 18: Adjuvant Chemotherapy for Osteosarcoma with Methotrexate Combination 38
Table 19: Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41
Table 20: Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41
Table 21: Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42
Table 22: Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42
Table 23: Osteosarcoma Therapeutics Most Promising Drugs Under Clinical Development, 2011 47
Table 24: Rexin-G, Summary of Phase II Trial Results, 2010 50
Table 25: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51
Table 26: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52
Table 27: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53
Table 28: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55
Table 29: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56
Table 30: Millennium Pharmaceuticals, Inc. Oncology Pipeline, 2011 61
Table 31: Millennium Pharmaceuticals, Inc Molecules in Pipeline for Osteosarcoma, 2011 61
Table 32: Millennium Pharmaceuticals, Inc Deals 62
Table 33: Merck & Co Oncology Inc Oncology Pipeline, 2011 64
Table 34: Merck & Co Molecules in Pipeline for Osteosarcoma, 2011 65
Table 35: Merck & Co., Inc. Deals 66
Table 36: ZIOPHARM Oncology Inc Oncology Pipeline, 2011 69
Table 37: ZIOPHARM Oncology Inc Molecules in Pipeline for Osteosarcoma, 2011 69
Table 38: ZIOPHARM Oncology Inc Deals 70
Table 39: Oncolytics Biotech Inc Oncology Pipeline, 2011 71
Table 40: Oncolytics Biotech Molecules in Pipeline for osteosarcoma, 2011 72
Table 41: Oncolytics Biotech- Deals 72
Table 42: Epeius Biotechnologies Corporation, Pipeline, 2011 72
Table 43: Epeius Biotechnologies Corporation, Pipeline, 2011 73
Table 44: Hawthorn Pharmaceuticals,Inc. Oncology Pipeline, 2011 73
Table 45: Hawthorn Pharmaceuticals,Inc Osteosarcoma Pipeline, 2011 73
Table 46: Hawthorn Pharmaceuticals,Inc Deals 74
Table 47: Osteosarcoma Therapeutics Market Future Players 74
Table 48: Licensing and Partnership Deals 75
1.2 List of Figures
Figure 1: Major Sites of Osteosarcoma 7
Figure 2: Staging of Osteosarcoma 10
Figure 3: Staging of Osteosarcoma 11
Figure 4: Bone X-ray of Osteosarcoma Patient 12
Figure 5: CT Scan of Osteosarcoma Patient 12
Figure 6: Chest X-ray of Osteosarcoma Patient 13
Figure 7: MRI of Osteosarcoma Patient 13
Figure 8: Bone Scan of Osteosarcoma Patient 14
Figure 9: PET Scan of Osteosarcoma Patient 14
Figure 10: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 20052010 18
Figure 11: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 20102017 19
Figure 12: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 20052010 20
Figure 13: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 20102017 21
Figure 14: Osteosarcoma Therapeutics Market, France, Revenue ($m), 20052010 22
Figure 15: Osteosarcoma Therapeutics Market, France, Forecast ($m), 20102017 23
Figure 16: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 20052010 24
Figure 17: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 20102017 25
Figure 18: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 20052010 26
Figure 19: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 20102017 27
Figure 20: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 20052010 28
Figure 21: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 20102017 29
Figure 22: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 20052010 30
Figure 23: Osteosarcoma Therapeutics Market, The UK, Forecast ($m), 20102017 31
Figure 24: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 20052010 32
Figure 25: Osteosarcoma Therapeutics Market, Japan, Forecast ($m), 20102017 33
Figure 26: Opportunity and Unmet Need in the Osteosarcoma Therapeutics Market, 2010 35
Figure 27: Osteosarcoma Therapeutics, Strategic Competitor Assessment, 2011 36
Figure 28: Osteosarcoma Therapeutics, Pipeline by Phase of Development, 2011 41
Figure 29: Osteosarcoma Therapeutics, Pipeline by Mechanism of Action, 2011 43
Figure 30: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, 2011 44
Figure 31: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, Description, 2011 45
Figure 32: Osteosarcoma Pipeline Products by Monotherapy and Combination therapy, 2011 46
Figure 33: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51
Figure 34: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52
Figure 35: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53
Figure 36: Osteosarcoma Therapeutics, Overall Sponsors, 2011 54
Figure 37: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55
Figure 38: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56
Figure 39: Osteosarcoma Therapeutics Market, Drivers and Restraints 2011 57
Figure 40: Implications for Future Market Competition in the Osteosarcoma Therapeutics Market, 2011 58
Figure 41: Osteosarcoma Therapeutics, Pipeline by Company, 2011 59
Figure 42: GlobalData Market Forecasting Model 80
Companies Mentioned
Millennium Pharmaceuticals, Inc.
Merck & Co
ZIOPHARM Oncology, Inc
Oncolytics Biotech Inc.
Epeius Biotechnologies Corporation
Hawthorn Pharmaceuticals, Inc.
To order this report:
Pathology Industry: Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Osteosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Osteosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Osteosarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Osteosarcoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Osteosarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Osteosarcoma Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Osteosarcoma Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Osteosarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Osteosarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Osteosarcoma Therapeutics market landscape? Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Osteosarcoma Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Symptoms 9
2.5 Staging of Osteosarcoma 9
2.5.1 American Joint Committee on Cancer (AJCC) Staging System 9
2.6 Diagnosis of Osteosarcoma 12
2.6.1 Imaging Techniques 12
2.6.2 Biopsy 15
2.6.3 Blood Tests 15
2.7 Treatment Options by Stage 15
2.7.1 Localized Osteosarcoma 15
2.7.2 Metastatic Osteosarcoma 15
2.7.3 Recurrent Osteosarcoma 15
2.8 Treatment and Management pattern of Osteosarcoma 15
2.8.1 Surgery 15
2.8.2 Radiation Therapy 16
2.8.3 Chemotherapy 16
2.9 GlobalData Pipeline Report Guidance 17
3 Osteosarcoma Therapeutics: Market Characterization 18
3.1 Osteosarcoma Therapeutics Market Size, Global, 2005-2010 18
3.2 Osteosarcoma Therapeutics Market Forecast, Global, 2010-2017 19
3.3 Osteosarcoma Therapeutics Market Size, The US, 2005-2010 20
3.4 Osteosarcoma Therapeutics Market Forecast, The US, 2010-2017 21
3.5 Osteosarcoma Therapeutics Market Size, France, 2005-2010 22
3.6 Osteosarcoma Therapeutics Market Forecast, France, 2010-2017 23
3.7 Osteosarcoma Therapeutics Market Size, Germany 2005-2010 24
3.8 Osteosarcoma Therapeutics Market Forecast, Germany, 2010-2017 25
3.9 Osteosarcoma Therapeutics Market Size, Italy, 2005-2010 26
3.10 Osteosarcoma Therapeutics Market Forecast, Italy, 2010-2017 27
3.11 Osteosarcoma Therapeutics Market Size, Spain, 2005-2010 28
3.12 Osteosarcoma Therapeutics Market Forecast, Spain, 2010-2017 29
3.13 Osteosarcoma Therapeutics Market Size, The UK, 2005-2010 30
3.14 Osteosarcoma Therapeutics Market Forecast, The UK, 2010-2017 31
3.15 Osteosarcoma Therapeutics Market Size, Japan, 2005-2010 32
3.16 Osteosarcoma Therapeutics Market Forecast, Japan, 2010-2017 33
3.17 Drivers and Barriers for the Osteosarcoma Therapeutics Market 34
3.17.1 Drivers for the Osteosarcoma Therapeutics Market 34
3.17.2 Barriers for the Osteosarcoma Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 35
4 Osteosarcoma Therapeutics: Competitive Assessment 36
4.1 Overview 36
4.1.1 Strategic Competitor Assessment 36
4.2 Major Marketed Product Profiles in the Osteosarcoma Therapeutics Market 37
4.2.1 Drugs Influencing Structure and Function of Deoxyribonucleic Acid (DNA) 37
4.2.2 Drugs Inhibiting Biosynthesis of Nucleic Acids 38
4.2.3 Drugs Interfering with Microtubule Assembly 39
4.3 Key Takeaway 39
5 Osteosarcoma Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Osteosarcoma Therapeutics Pipeline, Pipeline by Phases of Development 41
5.3.1 Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41
5.3.2 Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41
5.3.3 Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42
5.3.4 Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42
5.4 Osteosarcoma Therapeutics, Pipeline by Mechanism of Action 43
5.5 Technology Trends Analytic Framework 44
5.6 Osteosarcoma Therapeutics Pipeline by Monotherapy and Combination Therapy 46
5.7 Osteosarcoma Therapeutics, Promising Drugs Under Clinical Development 47
5.8 Molecule Profile for Promising Drugs Under Clinical Development 48
5.8.1 Ridaforolimus (MK8669, AP23573, Deforolimus) 48
5.8.2 Mepact (mifamurtide) 49
5.8.3 Rexin-G 49
5.9 Key Takeaway 50
6 Osteosarcoma Therapeutics: Clinical Trials Mapping 51
6.1 Clinical Trials by Country (US, EU5 and Japan) 51
6.2 Clinical Trials by Phase 52
6.3 Clinical Trials by Trial Status 53
6.4 Prominent Sponsors 54
6.5 Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials 56
7 Osteosarcoma Therapeutics: Strategic Assessment 57
7.1 Key Events Impacting the Future Market 57
7.2 Osteosarcoma Therapeutics: Implications for Future Market Competition 58
8 Osteosarcoma Therapeutics: Future Players 59
8.1 Introduction 59
8.2 Company Profiles 60
8.2.1 Millennium Pharmaceuticals, Inc. 60
8.2.2 Merck & Co 62
8.2.3 ZIOPHARM Oncology, Inc 68
8.2.4 Oncolytics Biotech Inc. 70
8.2.5 Epeius Biotechnologies Corporation 72
8.2.6 Hawthorn Pharmaceuticals, Inc. 73
8.2.7 Other Companies in the Osteosarcoma Therapeutics Market 74
9 Osteosarcoma Therapeutics: Licensing and Partnership Deals 75
10 Osteosarcoma Therapeutics: Appendix 76
10.1 Market Definitions 76
10.2 Abbreviations 76
10.3 Methodology 77
10.3.1 Coverage 77
10.3.2 Secondary Research 77
10.3.3 Forecasting 78
10.3.4 Primary Research 81
10.3.5 Expert Panel Validation 81
10.4 Contact Us 81
10.5 Disclaimer 81
10.6 Bibliography 82
1.1 List of Tables
Table 1: Histological Classification of Osteosarcoma - WHO 8
Table 2: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 20052010 18
Table 3: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 20102017 19
Table 4: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 20052010 20
Table 5: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 20102017 21
Table 6: Osteosarcoma Therapeutics Market, France, Revenue ($m), 20052010 22
Table 7: Osteosarcoma Therapeutics Market, France, Forecast ($m), 20102017 23
Table 8: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 20052010 24
Table 9: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 20102017 25
Table 10: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 20052010 26
Table 11: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 20102017 27
Table 12: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 20052010 28
Table 13: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 20102017 29
Table 14: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 20052010 30
Table 15: Osteosarcoma Therapeutics Market, The UK, Forecasts ($m), 20102017 31
Table 16: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 20052010 32
Table 17: Osteosarcoma Therapeutics Market, Japan, Forecasts ($m), 20102017 33
Table 18: Adjuvant Chemotherapy for Osteosarcoma with Methotrexate Combination 38
Table 19: Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41
Table 20: Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41
Table 21: Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42
Table 22: Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42
Table 23: Osteosarcoma Therapeutics Most Promising Drugs Under Clinical Development, 2011 47
Table 24: Rexin-G, Summary of Phase II Trial Results, 2010 50
Table 25: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51
Table 26: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52
Table 27: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53
Table 28: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55
Table 29: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56
Table 30: Millennium Pharmaceuticals, Inc. Oncology Pipeline, 2011 61
Table 31: Millennium Pharmaceuticals, Inc Molecules in Pipeline for Osteosarcoma, 2011 61
Table 32: Millennium Pharmaceuticals, Inc Deals 62
Table 33: Merck & Co Oncology Inc Oncology Pipeline, 2011 64
Table 34: Merck & Co Molecules in Pipeline for Osteosarcoma, 2011 65
Table 35: Merck & Co., Inc. Deals 66
Table 36: ZIOPHARM Oncology Inc Oncology Pipeline, 2011 69
Table 37: ZIOPHARM Oncology Inc Molecules in Pipeline for Osteosarcoma, 2011 69
Table 38: ZIOPHARM Oncology Inc Deals 70
Table 39: Oncolytics Biotech Inc Oncology Pipeline, 2011 71
Table 40: Oncolytics Biotech Molecules in Pipeline for osteosarcoma, 2011 72
Table 41: Oncolytics Biotech- Deals 72
Table 42: Epeius Biotechnologies Corporation, Pipeline, 2011 72
Table 43: Epeius Biotechnologies Corporation, Pipeline, 2011 73
Table 44: Hawthorn Pharmaceuticals,Inc. Oncology Pipeline, 2011 73
Table 45: Hawthorn Pharmaceuticals,Inc Osteosarcoma Pipeline, 2011 73
Table 46: Hawthorn Pharmaceuticals,Inc Deals 74
Table 47: Osteosarcoma Therapeutics Market Future Players 74
Table 48: Licensing and Partnership Deals 75
1.2 List of Figures
Figure 1: Major Sites of Osteosarcoma 7
Figure 2: Staging of Osteosarcoma 10
Figure 3: Staging of Osteosarcoma 11
Figure 4: Bone X-ray of Osteosarcoma Patient 12
Figure 5: CT Scan of Osteosarcoma Patient 12
Figure 6: Chest X-ray of Osteosarcoma Patient 13
Figure 7: MRI of Osteosarcoma Patient 13
Figure 8: Bone Scan of Osteosarcoma Patient 14
Figure 9: PET Scan of Osteosarcoma Patient 14
Figure 10: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 20052010 18
Figure 11: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 20102017 19
Figure 12: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 20052010 20
Figure 13: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 20102017 21
Figure 14: Osteosarcoma Therapeutics Market, France, Revenue ($m), 20052010 22
Figure 15: Osteosarcoma Therapeutics Market, France, Forecast ($m), 20102017 23
Figure 16: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 20052010 24
Figure 17: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 20102017 25
Figure 18: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 20052010 26
Figure 19: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 20102017 27
Figure 20: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 20052010 28
Figure 21: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 20102017 29
Figure 22: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 20052010 30
Figure 23: Osteosarcoma Therapeutics Market, The UK, Forecast ($m), 20102017 31
Figure 24: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 20052010 32
Figure 25: Osteosarcoma Therapeutics Market, Japan, Forecast ($m), 20102017 33
Figure 26: Opportunity and Unmet Need in the Osteosarcoma Therapeutics Market, 2010 35
Figure 27: Osteosarcoma Therapeutics, Strategic Competitor Assessment, 2011 36
Figure 28: Osteosarcoma Therapeutics, Pipeline by Phase of Development, 2011 41
Figure 29: Osteosarcoma Therapeutics, Pipeline by Mechanism of Action, 2011 43
Figure 30: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, 2011 44
Figure 31: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, Description, 2011 45
Figure 32: Osteosarcoma Pipeline Products by Monotherapy and Combination therapy, 2011 46
Figure 33: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51
Figure 34: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52
Figure 35: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53
Figure 36: Osteosarcoma Therapeutics, Overall Sponsors, 2011 54
Figure 37: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55
Figure 38: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56
Figure 39: Osteosarcoma Therapeutics Market, Drivers and Restraints 2011 57
Figure 40: Implications for Future Market Competition in the Osteosarcoma Therapeutics Market, 2011 58
Figure 41: Osteosarcoma Therapeutics, Pipeline by Company, 2011 59
Figure 42: GlobalData Market Forecasting Model 80
Companies Mentioned
Millennium Pharmaceuticals, Inc.
Merck & Co
ZIOPHARM Oncology, Inc
Oncolytics Biotech Inc.
Epeius Biotechnologies Corporation
Hawthorn Pharmaceuticals, Inc.
To order this report:
Pathology Industry: Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker